One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development

References

• Abouir K, Samer CF, Gloor Y, Desmeules JA, Daali Y. 2021. Reviewing data integrated for PBPK model development to predict metabolic drug-drug interactions: shifting perspectives and emerging trends. Front Pharmacol. 12:708299.
   PubMed Web of Science ®Google Scholar
• Adeyemi SA, Choonara YE. 2022. Recent patents on water-soluble polysaccharides for advanced drug delivery, tissue engineering and regenerative medicine. Pharm Pat Anal. 11(2):75–88.
   PubMed Web of Science ®Google Scholar
• Batta A, Kalra BS, Khirasaria R. 2020. Trends in FDA drug approvals over last 2 decades: an observational study. J Family Med Prim Care. 9(1):105–114.
   PubMedGoogle Scholar
• BBC. 2022. Parkinson’s test: woman who smelled disease on husband helps scientists. www.bbc.co.uk/news/uk-scotland-62795737.
   Google Scholar
• Bisanz JE, Spanogiannopoulos P, Pieper LM, Bustion AE, Turnbaugh PJ. 2018. How to determine the role of the microbiome in drug disposition. Drug Metab Dispos. 46(11):1588–1595.
   PubMed Web of Science ®Google Scholar
• Bomann W, Tinwell H, Jenkinson P, Kluxen FM. 2021. Metribuzin-induced non-adverse liver changes result in rodent-specific non-adverse thyroid effects via uridine 5′-diphospho-glucuronosyltransferase (UDPGT, UGT) modulation. Regul Toxicol Pharmacol. 122:104884.
   PubMed Web of Science ®Google Scholar
• Burden N, Kendrick J, Knight L, McGregor V, Murphy H, Punler M, Wijk H. 2017. Maximizing the success of bile duct cannulation studies in rats: recommendations for best practice. Lab Anim. 51(5):457–464.
   PubMed Web of Science ®Google Scholar
• Chapman K, Chivers S, Gliddon D, Mitchell D, Robinson S, Sangster T, Sparrow S, Spooner N, Wilson A. 2014. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discov Today. 19(5):528–532.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wong H. 2020. Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 12(7):672.
   PubMed Web of Science ®Google Scholar
• Clayton R, Holdsworth C, Tomczyk N, Giles K, Ujma J, Weston D. 2017. Evaluation of a cyclic mobility-enabled research platform with multiple-pass ion geometry for metabolite characterisation studies. 65th ASMS conference on mass spectrometry and allied topics poster.
   Google Scholar
• Code of Federal Regulations. 1992. Title 21 food and drugs chapter I food and drug administration department of health and human services subchapter D – drugs for human use part 316 orphan drugs.
   Google Scholar
• Corrigan BW. 2020. Artificial intelligence and machine learning: will clinical pharmacologists be needed in the next decade? The John Henry question. Clin Pharmacol Ther. 107(4):697–699.
   PubMed Web of Science ®Google Scholar
• De Maria D, Fahrni SM, Lozac’h F, Marvalin C, Walles M, Camenisch G, Wacker L, Synal H-A. 2021. Double trap interface: a novel gas interface for high throughput analysis of biomedical samples by AMS. Drug Metab Pharmacokinet. 39:100400.
   PubMed Web of Science ®Google Scholar
• EARA. 2022. EARA news digest 2022 – week 34.
   Google Scholar
• EFSA. 2019. Workshop on in vitro comparative metabolism studies in regulatory pesticide risk assessment. EFSA Journal EN-1618EFSA.
   Google Scholar
• European Chemicals Agency/European Food Safety Authority 2018. Guidance for the identification of endocrine disruptors in the context of regulations (EU) no 528/2012 and (EC) no 1107/2009.
   Google Scholar
• European Union. 2006. Regulation (EC) No.1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the registration, evaluation, authorization and restriction of chemicals. REACH J Eur Union L. 396:1–849.
   Google Scholar
• Ferreira DA, Rothbauer M, Conde JP, Ertl P, Oliveira C, Granja PL. 2021. A fast alternative to soft lithography for the fabrication of organ-on-a-chip elastomeric-based devices and microactuators. Adv Sci. 8(8).
   Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. 2018. Major depressive disorder: developing drugs for treatment. Guidance for Industry.
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. 2020a. In vitro drug interaction studies — cytochrome p450 enzyme- and transporter-mediated drug interactions guidance for industry. U.S. Department of Health and Human Services, Clinical Pharmacology.
   Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research. 2020b. Guidance for industry safety testing of drug metabolites. U.S. Department of Health and Human Services Revision 2, Pharmacology and Toxicology.
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. 2022a. Nonclinical considerations for mitigating nonhuman primate supply constraints arising from the COVID-19 pandemic guidance for industry.
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. 2022b. Clinical pharmacology considerations for human radiolabeled mass balance studies guidance for industry draft guidance. U.S. Department of Health and Human Services, Clinical Pharmacology.
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. 2022c. Clinical pharmacology considerations for the development of oligonucleotide therapeutics; draft guidance for industry. U.S. Department of Health and Human Services.
   Google Scholar
• Forman L. 1993. Medication: reasons and interventions for noncompliance. J Psychosoc Nurs Ment Health Serv. 31(10):23–25.
   PubMedGoogle Scholar
• Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, Wang Y. 2019. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration’s office of clinical pharmacology. J Pharm Sci. 108(1):21–25.
   PubMed Web of Science ®Google Scholar
• Heining P, Ruysschaert T. 2016. The use of minipig in drug discovery and development: pros and cons of minipig selection and strategies to use as a preferred nonrodent species. Toxicol Pathol. 44(3):467–473.
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2009. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals Step 5. EMA/CPMP/ICH/286/1995.
   Google Scholar
• Isbell J, Yuan D, Torrao L, Gatlik E, Hoffmann L, Wipfli P. 2019. Plasma protein binding of highly bound drugs determined with equilibrium gel filtration of nonradiolabeled compounds and LC-MS/MS detection. J Pharm Sci. 108(2):1053–1060.
   PubMed Web of Science ®Google Scholar
• Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. 2021. Precision medicine, ai, and the future of personalized health care. Clin Transl Sci. 14(1):86–93.
   PubMed Web of Science ®Google Scholar
• Kendrick J, Stow R, Ibbotson N, Adjin-Tettey G, Murphy B, Bailey G, Miller J, Helleberg H, Finderup Grove M, Øvlisen K, et al. 2020. A novel welfare and scientific approach to conducting dog metabolism studies allowing dogs to be pair housed. Lab Anim. 54(6):588–598.
   PubMed Web of Science ®Google Scholar
• Kilford P, Khoshaein N, Southall R, Gardner I. 2022. Physiologically-based pharmacokinetic models of CYP2D6 substrate and inhibitors nebivolol, cinacalcet and mirabegron to simulate drug-drug interactions. Eur J Drug Metab Pharmacokinet. 47(5):699–710.
   PubMed Web of Science ®Google Scholar
• King L, Kotian A, Jairaj M. 2014. Introduction of a routine quan/qual approach into research DMPK: experiences and evolving strategies. Bioanalysis. 6(24):3337–3348.
   PubMed Web of Science ®Google Scholar
• Kluxen FM, Totti S, Maas W, Toner F, Page L, Webbley K, Nagane R, Mingoia R, Whitfield C, Kendrick J, et al. 2022. An OECD TG 428 study ring trial with 14C-Caffeine demonstrating repeatability and robustness of the dermal absorption in vitro method. Regul Toxicol Pharm. 132:105184.
   PubMed Web of Science ®Google Scholar
• Kratochwil NA, Dueker SR, Muri D, Senn C, Yoon H, Yu B-Y, Lee G-H, Dong F, Otteneder M. 2018. Nanotracing and cavity-ring down spectroscopy: a new ultrasensitive approach in large molecule drug disposition studies. PLOS One. 13(10):e0205435.
   PubMed Web of Science ®Google Scholar
• Kraus VB. 2018. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 14(6):354–362.
   PubMed Web of Science ®Google Scholar
• Lee SC, Arya V, Yang X, Volpe DA, Zhang L. 2017. Evaluation of transporters in drug development: current status and contemporary issues. Adv Drug Deliv Rev. 116:100–118.
   PubMed Web of Science ®Google Scholar
• Li K, Peng S, Ma T, Wu W, Jiang Y, Cui B, Zhang A, Sun J, Guo Z-Y, Chen J. 2022. Preliminary results of positive ion mass spectrometry based on a 2.45 GHz ECR ion source and a non-metallic gas target. J Phys: Conf Ser. 2244(1):012093.
   Google Scholar
• Liao KH, Udata C, Yin D, Sewell KL, Kantaridis C, Alvarez DF, Meng X. 2020. A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing. Br J Clin Pharmacol. 86(11):2182–2191.
   PubMed Web of Science ®Google Scholar
• Madden JC, Pawar G, Cronin MTD, Webb S, Tan Y-M, Paini A. 2019. In silico resources to assist in the development and evaluation of physiologically-based kinetic models. Comput Toxicol. 11:33–49.
   Google Scholar
• Mattis C, Bratcher N, Burns M, Carosino C, de Zafra C, Fancher RM, Georgi K, Graff C, Hukkanen RR, Johnson C, et al. 2022. Increasing the reuse of protein non-naïve nonhuman primates in pharmaceutical drug discovery and development: an overview and industry position on the challenges and benefits. Int J Toxicol. 41(4):291–296.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. 2021. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 20(2):101–124.
   PubMed Web of Science ®Google Scholar
• Moore SA. 2018. Reducing the respiratory minute volume and improving animal welfare in inhalation large animal studies by using a 3d printer and designing specific masks. Envigo Poster SciPos. 854.
   Google Scholar
• Organisation for Economic Co-operation and Development. 2004. Test No. 428: skin absorption: in vitro method, OECD guidelines for the testing of chemicals, section 4. OECD Publishing.
   Google Scholar
• Ohtsu Y, Tanaka S, Igarashi H, Kakehi M, Mori T, Nakamura T, Ohashi R, Shimizu H, Yasuda Y, Okayama T, et al. 2021. Analytical method validation for biomarkers as a drug development tool: points to consider. Bioanalysis. 13(18):1379–1389.
   PubMed Web of Science ®Google Scholar
• Organ-On-A-Chip Technologies. 2018. Current status and translatability of data. Summaries and conclusions of a workshop debate in May 2018 between experts from industry, academia and the Medicines and Healthcare products Regulatory Agency (MHRA) on the subject of OOAC technologies.
   Google Scholar
• Osório LA, Silva E, Mackay RE. 2021. A review of biomaterials and scaffold fabrication for organ-on-a-chip (OOAC) systems. Bioengineering. 8(8):113.
   PubMed Web of Science ®Google Scholar
• Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. 2021. Artificial intelligence in drug discovery and development. Drug Discov Today. 26(1):80–93.
   PubMed Web of Science ®Google Scholar
• Prior H, Baldrick P, Beken S, Booler H, Bower N, Brooker P, Brown P, Burlinson B, Burns-Naas LA, Casey W, et al. 2020. Opportunities for use of one species for longer-term toxicology testing during drug development: a cross-industry evaluation. Regul Toxicol Pharmacol. 113:104624.
   PubMed Web of Science ®Google Scholar
• PsychedelicHealth. 2022. FDA clearance for clinical trial exploring psilocybin for MDD. UK: Psychedelic Press.
   Google Scholar
• Regulatory Focus™. 2022. FDA finalizes guidance for drugs and biologics containing nanomaterials. News Articles.
   Google Scholar
• Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, et al. 2018. A decade in the MIST: learnings from investigations of drug metabolites in drug development under the "metabolites in safety testing" regulatory guidance. Drug Metab Dispos. 46(6):865–878.
   PubMed Web of Science ®Google Scholar
• Shou WZ. 2020. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal. 10(3):201–208.
   PubMed Web of Science ®Google Scholar
• Sparrow SS, Robinson S, Bolam S, Bruce C, Danks A, Everett D, Fulcher S, Hill RE, Palmer H, Scott EW, et al. 2011. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regul Toxicol Pharmacol. 61(2):222–229.
   PubMed Web of Science ®Google Scholar
• Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, Mapplebeck JC, Wei P, Zhan S, Zhang S, et al. 2011. The rat grimace scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol Pain. 7:55.
   PubMed Web of Science ®Google Scholar
• Stow R, Kendrick J, Ibbotson N, Adjin-Tettey G, Murphy B, Trojca R, Miller J, Konradsen G, Øvlisen K, Helleberg H, et al. 2021. A new group housing approach for non-human primate metabolism studies. J Pharmacol Toxicol Methods. 107:106947.
   PubMed Web of Science ®Google Scholar
• Summerfield S, Jeffrey P. 2009. Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opin Drug Discov. 4(3):207–218.
   PubMed Web of Science ®Google Scholar
• Teutonico D, Block M, Kuepfer L, Solodenko J, Eissing T, Coboeken K. 2022. PK‐Sim ® for modeling oral drug delivery of modified‐release formulations.
   Google Scholar
• Tsunoda SM, Gonzales C, Jarmusch AK, Momper J, Ma J. 2021. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability. Clin Pharmacokinet. 60(8):971–984.
   PubMed Web of Science ®Google Scholar
• US Congress. 2016. The Frank R. Lautenberg chemical safety for the 21st century act. Pub L. 114–182.
   Google Scholar
• Van Campenhout R, Muyldermans S, Vinken M, Devoogdt N, De Groof TWM. 2021. Therapeutic nanobodies targeting cell plasma membrane transport proteins: a high-risk/high-gain endeavor. Biomolecules. 11(1):63.
   PubMed Web of Science ®Google Scholar
• Vora LK, Moffatt K, Tekko IA, Paredes AJ, Volpe-Zanutto F, Mishra D, Peng K, Raj Singh Thakur R, Donnelly RF. 2021. Microneedle array systems for long-acting drug delivery. Eur J Pharm Biopharm. 159:44–76.
   PubMed Web of Science ®Google Scholar
• Vrbanac J, Slauter R. 2017. A comprehensive guide to toxicology in nonclinical drug development (Second Edition). In: Chapter 3 - ADME in Drug Discovery. Amsterdam (NL): Elsevier; p. 39–67.
   Google Scholar